Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens

Current Infectious Disease Reports

Volumn 15, Issue 2, 2013, Pages 109-115

  Levison, Matthew E ^a,b,c   Kaye, Donald ^b  

^a DREXEL UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c not available   (United States)

Author keywords

Amoxicillin clavulanic acid; AmpC beta lactamase; Aztreonam; Beta lactam beta lactamase inhibitor combinations; Carbapenemase; Carbapenems; Cefepime; Complicated; Drug resistance; ESBL; Fluoroquinolones; Fosfomycin; Gram negative bacilli; Infection; Nitrofurantoin; Third generation cephalosporins; Treatment guidelines; Trimethoprim sulfamethoxazole; Urinary tract; Uropathogens

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHANESULFONATE; COLISTIN; FOSFOMYCIN; LEVOFLOXACIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; PRODRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CYSTITIS; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; GRAM NEGATIVE BACTERIUM; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PROTEUS; PROVIDENCIA; PSEUDOMONAS; PYELONEPHRITIS; SERRATIA; SINGLE DRUG DOSE; TREATMENT DURATION; URINARY TRACT INFECTION; URINE CULTURE;

EID: 84877924611     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0315-7     Document Type: Article

References (38)

1. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65 suppl 3:iii25-33. This is one of the few reviews of the subject of treatment of complicated UTIs caused by multidrug-resistant gram-negative bacteria.
2. Nicolle L. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16:349-60.
3. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Curr Infect Dis Rep. 2008;10:499-504.
4. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.
5. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010;35:316-21. This article describes the worldwide dissemination of an ESBL-producing E. coli.
6. Rodríguez-Baño J, Navarro MD. Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective. Clin Microbiol Infect. 2008;14 Suppl 1:104-10.
7. Johnson JR, Johnston B, Connie C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010;51:286-94. This describes the dissemination of an ESBL-producing E. coli in the U.S.
8. Paterson DL. Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended- spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460-3.
9. Ahmad M, Urban C, Mariano N, et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 1999;29:352-5.
10. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymixin B and sulbactam. Lancet. 1994;344:1329-32.
11. Gavin PJ, Suseno MT, Thomson Jr RB, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006;50:2244-7.
12. Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomcyin for the treatment of multidrug resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43-50. This paper is a review of the use of fosfomycin for treatment of urinary tract infection caused by multidrug-resistant Enterobacteriaceae.UTIs.
13. Martínez-Martínez L, Pascual A, Hernández- Allés S, et al. Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother. 1999;43:1669-73.
14. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440-58.
15. CDC. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR. 2009;58:256-60.
16. Kumarasamy KK, Tolman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-602.
17. Walsh TR, Weeks J, Livermore DM, et al. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355-62.
18. Arpin C, Noury P, Boraud D, et al. NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel. Antimicrob Agents Chemother. 2012;56:3432-4.
19. CDC. Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012. MMWR. 2012;61:446-8. This is a report of urinary tract infection caused by carbapenemase-resistant bacteria in the U.S.
20. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-20. These are the guidelines on treatment of uncomplicated UTIs in women from the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Patients with complicated UTIs may not be recognized initially to have a complication and, therefore, will be started on treatment for uncomplicated infection.
21. Falagas ME, Kotsantis IK, Vouloumanou EK, et al. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect. 2009;58:91-102.
22. Bleidorn J, Gágyor I, Kochen MM, et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? - results of a randomized controlled pilot trial. BMC Med. 2010;8:30. This is a double-blind, randomized controlled drug trial that shows the noninferiority of ibuprofen, as compared with ciprofloxacin, each given for 3 days for treatment of symptomatic uncomplicated UTIs in healthy women 18-85 years of age. However, up to day 9, 12/36 (33%) of patients in the ibuprofen group received secondary antibiotic treatment due to ongoing or worsening symptoms, as compared with 6/33 (18%) in the ciprofloxacin group (nonsignificant).
23. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1862-77. This is a meta-analysis of randomized controlled trials, which involved mostly nonpregnant female patients with cystitis. It found no difference between fosfomycin and comparators in clinical and microbiological success/relapse/reinfection.
24. Ronald AR, Boutros P, Mourtada H. Bacteriuria localization and response to single-dose therapy in women. JAMA. 1976;235:1854-6.
25. Chen YH, Ko WC, Hsueh PR. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone- resistant uropathogens. Eur J Clin Microbiol Infect Dis. 2012;31:1699-704.
26. Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect. 2011;62:159-64.
27. Jeon JH, Kim K, Han WD, et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother. 2012;56:3043-6.
28. Johnson CC, Livornese L, Gold MJ, et al. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. J Antimicrob Chemother. 1995;35:765-73.
29. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228-36.
30. Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from micro biological and clinical studies. J Antimicrob Chemother. 2008;62:895-904.
31. Li J, Milne RW, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53:837-40.
32. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65:1019-27.
33. Pogue JM, Marchaim D, Kaye D, et al. Re-visiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy. 2011;31:912-21.
34. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879-84.
35. Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin Microbiol. 2008;46:1892-3.
36. Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54:1699-709.
37. Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung. 2005;55:420-7. This is a paper on long-term use of fosfomycin for oral prophylaxis of recurrent UTIs in women.
38. Gupta K, Hooton TM. Duration of therapy for urinary tract infection: the long and the short of it. Clin Infect Dis. 2004;39:665-6.